Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
出版年份 2023 全文链接
标题
Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
作者
关键词
-
出版物
SEMINARS IN LIVER DISEASE
Volume -, Issue -, Pages -
出版商
Georg Thieme Verlag KG
发表日期
2023-11-07
DOI
10.1055/s-0043-1776127
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
- (2023) Shengwei Tao et al. Frontiers in Immunology
- Transforming Cold Tumors into Hot Ones with a Metal–Organic Framework-Based Biomimetic Nanosystem for Enhanced Immunotherapy
- (2023) Manman Xu et al. ACS Applied Materials & Interfaces
- PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma
- (2023) Petros Fessas et al. Future Oncology
- Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
- (2023) Matthias Pinter et al. Lancet Gastroenterology & Hepatology
- Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
- (2022) Uasim Harkus et al. SEMINARS IN CANCER BIOLOGY
- Myeloid‑derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma
- (2022) Takahiro Tomiyama et al. Oncology Letters
- Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
- (2022) Hans Urban et al. Frontiers in Immunology
- RNF135 Promoter Methylation Is Associated With Immune Infiltration and Prognosis in Hepatocellular Carcinoma
- (2022) Xiao Wang et al. Frontiers in Oncology
- Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?
- (2022) Claudia Angela Maria Fulgenzi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
- (2022) Yuting Lu et al. Journal of Hematology & Oncology
- PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma
- (2022) Chuan-Yuan Wei et al. JOURNAL OF HEPATOLOGY
- Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma
- (2022) Rongfeng Shi et al. Aging-US
- Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
- (2022) Qingqing Xie et al. Frontiers in Oncology
- Immune checkpoint inhibitor resistance in hepatocellular carcinoma
- (2022) Zhijie Wang et al. CANCER LETTERS
- Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
- (2021) Ilario Giovanni Rapposelli et al. Cancers
- The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
- (2021) Zongcai Liu et al. Cancer Communications
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
- (2021) J. Liu et al. Clinical & Translational Oncology
- Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma
- (2021) Won‐Mook Choi et al. LIVER INTERNATIONAL
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
- (2021) Weiqin Yang et al. Science Translational Medicine
- Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma
- (2021) Qijun Li et al. Frontiers in Immunology
- Immune Aging and Immunotherapy in Cancer
- (2021) Melanie Kaiser et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
- (2021) Kyoko Oura et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune PET Imaging
- (2021) Osigbemhe Iyalomhe et al. RADIOLOGIC CLINICS OF NORTH AMERICA
- Comprehensive Analysis of the Immune Infiltrates and PD-L1 of m6A RNA Methylation Regulators in Hepatocellular Carcinoma
- (2021) Yangtao Xu et al. Frontiers in Cell and Developmental Biology
- Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review
- (2021) Miaozhen Lin et al. Translational Lung Cancer Research
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- (2021) Golnaz Morad et al. CELL
- Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
- (2021) Kazuki Maesaka et al. HEPATOLOGY RESEARCH
- The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?
- (2021) Xin Hu et al. International Journal of Biological Sciences
- Nanomaterials targeting tumor associated macrophages for cancer immunotherapy
- (2021) Caiyan Zhao et al. JOURNAL OF CONTROLLED RELEASE
- Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
- (2021) Jia-Cheng Lu et al. Journal of Hematology & Oncology
- Systemic treatment of hepatocellular carcinoma: An EASL position paper
- (2021) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Immunotherapies for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC
- (2021) Sara Lewis et al. Abdominal Radiology
- Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
- (2021) Dong Ho Lee et al. Frontiers in Medicine
- Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways
- (2021) Mahshid Deldar Abad Paskeh et al. Journal of Hepatocellular Carcinoma
- A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma
- (2021) Gouri Pandya et al. SEMINARS IN CANCER BIOLOGY
- Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World
- (2020) Hanzhi Cui et al. OncoTargets and Therapy
- Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
- (2020) Lin Shui et al. Frontiers in Immunology
- Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications
- (2020) Pierre Decazes et al. Cancers
- Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
- (2020) Maxime Frelaut et al. BIODRUGS
- Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer
- (2020) Giuseppe Lo Russo et al. Current Oncology Reports
- Towards a more precise therapy in cancer: Exploring epigenetic complexity
- (2020) Fernando P. Cossío et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- The role of gut microbiota in cancer treatment: friend or foe?
- (2020) Wing Yin Cheng et al. GUT
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Effectiveness of anti-PD-1 for hepatocellular carcinoma – Authors' reply
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- 998P The biomarkers associated with hyperprogression (HP) to immune checkpoint inhibitors (ICIs) in Chinese hepatocellular carcinoma (HCC) patients
- (2020) C. Wei et al. ANNALS OF ONCOLOGY
- Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma
- (2020) Laia Bassaganyas et al. CLINICAL CANCER RESEARCH
- Hyperprogression in hepatocellular carcinoma: Illusion or reality?
- (2020) Stephen L. Chan JOURNAL OF HEPATOLOGY
- Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
- (2020) Chang Gon Kim et al. JOURNAL OF HEPATOLOGY
- High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma
- (2020) Beng Yang et al. ONCOGENE
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells
- (2020) Dong Li et al. ONCOLOGY RESEARCH
- Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma
- (2020) Stephan Spahn et al. Cancers
- Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
- (2020) Jordi Rimola et al. EUROPEAN JOURNAL OF RADIOLOGY
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
- (2019) Takeshi Tanoue et al. NATURE
- Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series
- (2019) Daniel Jiahao Wong et al. Immunotherapy
- Endoplasmic Reticulum Stress Promotes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate PD-L1 Expression in Macrophages
- (2019) Jiatao Liu et al. HEPATOLOGY
- Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort
- (2019) Bernhard Scheiner et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience
- (2019) Luca Rinaldi et al. DIGESTIVE DISEASES AND SCIENCES
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice
- (2019) Yu Zheng et al. Molecular Cancer
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Hyperprogression during immunotherapy: do we really want to know?
- (2019) S Champiat et al. ANNALS OF ONCOLOGY
- IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
- (2019) Li-Chuan Chan et al. JOURNAL OF CLINICAL INVESTIGATION
- Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study
- (2019) Xubiao Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma
- (2019) Ling Deng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
- (2019) Yi Zheng et al. Journal for ImmunoTherapy of Cancer
- Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
- (2019) Ilaria Alborelli et al. JOURNAL OF PATHOLOGY
- Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma
- (2019) Bettina Langhans et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma
- (2019) Shaw M. Akula et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation
- (2019) Ssu-Chuan Lai et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma
- (2019) Jingnan Wang et al. CLINICAL NUCLEAR MEDICINE
- Hyperprogression as a Distinct Outcome after Immunotherapy
- (2018) J. Fuentes-Antrás et al. CANCER TREATMENT REVIEWS
- Cancer epigenetics: Moving forward
- (2018) Angela Nebbioso et al. PLoS Genetics
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients
- (2018) Jung Youn Kim et al. NEURO-ONCOLOGY
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
- (2018) Diana Llopiz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Evaluation of Post-Stereotactic Body Radiation Therapy Response Assessment for Hepatocellular Carcinoma: An Appraisal of RECIST, m-RECIST and WHO Criteria
- (2018) D.J. Godfrey et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
- (2018) Wenliang Tan et al. EBioMedicine
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- Structural basis for alpha fetoprotein-mediated inhibition of caspase-3 activity in hepatocellular carcinoma cells
- (2017) Bo Lin et al. INTERNATIONAL JOURNAL OF CANCER
- The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
- (2017) Marija Mojic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Transient Increases of Serum AFP and PIVKA-II Levels After Proton Therapy Do Not Necessarily Indicate Progression of Hepatocellular Carcinoma
- (2017) M. Yoshida et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis
- (2017) C. Floridi et al. MEDICAL ONCOLOGY
- Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
- (2017) Jianhua Liu et al. ONCOLOGY REPORTS
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer
- (2017) Dongfang Tang et al. Oncotarget
- Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis
- (2017) Lejia Sun et al. Oncotarget
- Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response
- (2016) Y. Kato et al. ANNALS OF ONCOLOGY
- Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells
- (2016) Andrea Kristina Horst et al. Cellular & Molecular Immunology
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
- (2016) Simone Jueliger et al. Epigenetics
- Wnt signaling networks in autism spectrum disorder and intellectual disability
- (2016) Vickie Kwan et al. Journal of Neurodevelopmental Disorders
- Report of two cases of pseudoprogression in patients with non–small cell lung cancer treated with nivolumab—including histological analysis of one case after tumor regression
- (2016) Junko Tanizaki et al. LUNG CANCER
- TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells
- (2016) Nathan Ungerleider et al. MOLECULAR CARCINOGENESIS
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection
- (2015) Chisato Okajima et al. AMERICAN JOURNAL OF SURGERY
- Improving cancer immunotherapy with DNA methyltransferase inhibitors
- (2015) Mohammad H. Saleh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Histone Deacetylase HDAC8 Promotes Insulin Resistance and -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma
- (2015) Y. Tian et al. CANCER RESEARCH
- Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process
- (2015) Xavier Adhoute et al. JOURNAL OF HEPATOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells
- (2015) Xin Wan et al. Oncotarget
- Controlling T cell senescence in the tumor microenvironment for tumor immunotherapy
- (2015) Jian Ye et al. OncoImmunology
- A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child–Pugh Scores of 5 or 6
- (2015) Hung-Hsu Hung et al. MEDICINE
- Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
- (2014) Vassiliki A. Boussiotis et al. CANCER JOURNAL
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
- (2013) Wolfgang Sieghart et al. HEPATOLOGY
- Understanding immunosenescence to improve responses to vaccines
- (2013) Jörg J Goronzy et al. NATURE IMMUNOLOGY
- The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells
- (2013) Shiguo Zhu et al. PHARMACEUTICAL RESEARCH
- Human T Cell Aging and the Impact of Persistent Viral Infections
- (2013) T. Fülöp et al. Frontiers in Immunology
- The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
- (2012) B. Costantini et al. HAEMATOLOGICA
- PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
- (2012) John Dulos et al. JOURNAL OF IMMUNOTHERAPY
- Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans
- (2012) Rafael Solana et al. SEMINARS IN IMMUNOLOGY
- Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors
- (2009) Pascal Wolter et al. ACTA ONCOLOGICA
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
- (2009) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease
- (2009) I. Kryczek et al. CANCER RESEARCH
- Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
- (2009) K. Wu et al. CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Role of Kupffer cells in the induction of tolerance of orthotopic liver transplantation in rats
- (2008) Yong Chen et al. LIVER TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started